Cyclopeptide Utilizing Patents (Class 514/2.9)
  • Patent number: 10357535
    Abstract: Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 23, 2019
    Assignee: Hospira Australia Pty Ltd
    Inventors: Jim Alexiou, Andrew Malcolm Knill, Noel Norris, Darryl Whittaker
  • Patent number: 10286056
    Abstract: High loading of lipophilic pharmacological agents (in particular, lipophilic immunopotentiators) in oil-in-water emulsions can result in crystallisation of the lipophilic agent. To overcome this problem the invention uses an oil-in-water emulsion in combination with a crystallisation inhibitor, and this combination provides emulsions which can be loaded with high levels of lipophilic pharmacological agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Patent number: 10105414
    Abstract: The present invention relates to a pharmaceutical composition comprising a (poly)peptide which comprises or consists of QEP or a QEP derivative thereof a nucleic acid molecule encoding said (poly)peptide or a vector comprising said nucleic acid molecule, for use in the prevention or in the treatment of a disease or disorder caused by, physiologically linked to or associated with glucose and/or galactose uptake, wherein said pharmaceutical composition is to be administered under a high-sugar condition. Furthermore, the pharmaceutical composition of the invention is for use in increasing insulin sensitivity. The invention further relates to a food composition comprising said (poly)peptide. The invention further relates to a method of screening for and/or identifying a compound suitable to prevent or treat said disease or disorder under a high-sugar condition.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: October 23, 2018
    Assignee: Julius-Maximilians-Universität Würzburg
    Inventors: Alexandra Friedrich, Jürgen Groll, Hermann Koepsell, Maike Veyhl-Wichmann
  • Patent number: 9850276
    Abstract: Both JNK and LRRK2 are associated with Parkinson's disease (PD), myocardial infarction (MI), and other medical disorders. Here we report a reasonably selective and potent kinase inhibitors (e.g., compounds 6 and 10) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. 6 also exhibited good cell potency, inhibited LRRK2:G2019S induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: December 26, 2017
    Assignee: The Scripps Research Institute
    Inventors: Yangbo Feng, Philip Lo Grasso
  • Patent number: 9718763
    Abstract: A process of preparing olefins of the formula (I) is described herein: with R1 being a substituted or unsubstituted (C1-C30)hydrocarbyl, and R2 being a substituted or unsubstituted (C1-C20)hydrocarbyl. The process includes reacting a compound of formula (II) wherein Ar is chosen from in the presence of a palladium-based catalyst and an organic solvent. A process of preparing olefins of the formula (III) is also described: with R3 being a substituted or unsubstituted (C1-C30)hydrocarbyl, R4 being a substituted or unsubstituted (C1-C20)hydrocarbyl, and R5 being a substituted or unsubstituted (C1-C30) hydrocarbyl. The process includes reacting a compound of formula (IV) wherein Ar is chosen from with a compound of formula (V) wherein Ar is chosen from in the presence of a palladium-based catalyst and an organic solvent.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 1, 2017
    Assignee: Regents of the University of Minnesota
    Inventors: William Baker Tolman, Marc A. Hillmyer, Alex John, Levi Thomas Hogan
  • Patent number: 9446090
    Abstract: Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 20, 2016
    Assignee: AMICROBE, INC.
    Inventors: Michael P. Bevilacqua, Diego Benitez, Jarrod A. Hanson
  • Patent number: 9255062
    Abstract: The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are amide derivatives which can be synthesized by reaction of the corresponding fatty acid halide with a naturally occurring amino acid, phenylalanine or a suitable derivative thereof, and which are in a poorly hygroscopic, easily weighable form, stable to acids and alkalis and able to release the acid at the small and large bowel level in a constant manner over time. They do not have disagreeable odors and are practically tasteless, thus allowing the manufacture of preparations for oral administration also suitable for the therapy of chronic diseases and in the pediatric field.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: February 9, 2016
    Inventors: Roberto Berni Canani, Antonio Calignano, Orazio Mazzoni, Orietta Mazzoni, Anna Coruzzo
  • Patent number: 9233989
    Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: January 12, 2016
    Assignee: Council of Scientific & Industrial Research
    Inventors: Dumbala Srinivasa Reddy, Seetharam Singh Balamkundu, Remya Ramesh
  • Patent number: 9101574
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20150139973
    Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
  • Publication number: 20150141325
    Abstract: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the ?E pathway in Escherichia coli.
    Type: Application
    Filed: December 19, 2014
    Publication date: May 21, 2015
    Inventors: Sarah Ellen Ades, Kenneth Charles Keiler
  • Publication number: 20150132382
    Abstract: The present invention provides compositions comprising fosfomycin or a pharmaceutically acceptable salt, solvate or prodrug thereof (e.g., fosfomycin disodium) alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infections, which include administering an effective amount of fosfomycin or a pharmaceutically acceptable salt, solvate or a prodrug thereof (e.g., fosfomycin disodium) alone or in combination with an antibacterial agent.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya
  • Publication number: 20150133366
    Abstract: C. difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea. Unfortunately, antibiotic therapy remains as the standard treatment for this antibiotic-induced disease and relapses are common. Antibiotic treatment typically is given for 10 to 14 days for initial or second episode of CDI. For recurrent episodes, more prolonged courses are recommended. It is disclosed herein that lower dose or shorter course of the antimicrobial treatment is sufficient to treat the disease and prevent recurrent disease by enabling a good immunologic response to infection, and perhaps also by better preserving normal flora, thus protecting against relapses or reinfection.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Richard L. Guerrant, Cirle Alcantara Warren, John Hudson Moore, II, Edward van Opstal
  • Publication number: 20150126432
    Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 7, 2015
    Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
  • Publication number: 20150110767
    Abstract: Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: PAUL B. SAVAGE, CARL A. GENBERG, MICHAEL D. TRIPLETT
  • Patent number: 9006173
    Abstract: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: April 14, 2015
    Assignee: University of Kentucky Research Foundation
    Inventors: Noel R. Monks, Shuqian Liu, Jeffrey A. Moscow
  • Patent number: 9006392
    Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: April 14, 2015
    Assignee: Novacta Biosystems Limited
    Inventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
  • Patent number: 8987194
    Abstract: A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 24, 2015
    Assignees: University College Cork-National University of Ireland, Cork, Agriculture and Food Development Authority
    Inventors: Colin Hill, Paul Cotter, Paul R. Ross, Desmond Field
  • Publication number: 20150080292
    Abstract: This invention provides new cyclic lipopeptide antibiotic Locillomycin (Locillomycin-A, Locillomycin-B, Locillomycin-C) that display very strong antifungal, antibacterial, antivirus activities in a variety of contexts in vitro; methods of making and using the compounds, wherein Locillomycin-A, Locillomycin-B and Locillomycin-C are derived and purified from the culture of Bacillus subtilis Bs916.
    Type: Application
    Filed: February 26, 2014
    Publication date: March 19, 2015
    Inventor: Chuping Luo
  • Patent number: 8981048
    Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: March 17, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
  • Patent number: 8969513
    Abstract: Disclosed are a caspofungin analog and applications thereof. The caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable salts thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of the compound.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: March 3, 2015
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
  • Patent number: 8969514
    Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: March 3, 2015
    Assignee: Synergy Pharmaceuticals, Inc.
    Inventor: Kunwar Shailubhai
  • Publication number: 20150056160
    Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia—inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
    Type: Application
    Filed: February 24, 2014
    Publication date: February 26, 2015
    Inventors: Nicholas Bachynsky, Woodie Roy
  • Patent number: 8962550
    Abstract: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the ?E pathway in Escherichia coli.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 24, 2015
    Assignee: The Penn State Research Foundation
    Inventors: Sarah Ellen Ades, Kenneth Charles Keiler
  • Publication number: 20150045286
    Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 12, 2015
    Inventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
  • Publication number: 20150045288
    Abstract: The present invention relates to anti-contaminant composition comprising a cell-free fermentation product of one or more Bacillus subtilis strains (e.g., selected from the group consisting of: 22C-P1, 15A-P4, 3A-P4, LSSA01, ABP278, BS 2084 and BS 18); wherein said fermentation product comprises one or more compounds selected from the group consisting of: a lipopeptide, a polyketide, a bacillibactin, a bacilysin, an anticapsin, a plantazolicin, a LCI, a homologue of a plantazolicin and a homologue of a LCI. In addition, the present invention further relates to methods of preparing the compositions, methods of using the composition, products comprising the composition and uses thereof.
    Type: Application
    Filed: February 20, 2013
    Publication date: February 12, 2015
    Inventors: Tina Mygind, George H. Weber, Connie Benfeldt, Ashley Ann Hibberd, Rebecca Joy Landrum, Panagiotis Chanos, Gregory R. Siragusa, Matthew James Hundt
  • Publication number: 20150045289
    Abstract: The present invention relates to the method of pre-preparing pharmaceutical compositions for therapeutic uses, particularly pre-preparing medications for treating patients (e.g., cancer patients and the like) by intravenous infusion.
    Type: Application
    Filed: July 14, 2014
    Publication date: February 12, 2015
    Inventors: MICHAEL L. WEST, Tracey J. BROWN
  • Patent number: 8946145
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: February 3, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu
  • Patent number: 8946144
    Abstract: The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 3, 2015
    Assignee: The Medicines Company
    Inventors: Kelly Tanaka, Stephane Ciblat, Adel Rafai Far, Evelyne Dietrich
  • Publication number: 20150030566
    Abstract: Compositions containing one or more tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives and analogues thereof, are described for controlling antimicrobial growth on plants, plant material or plant growth media, and methods for controlling or preventing the growth of microbial pathogens, and in particular fungal pathogens, on plants, plant parts and plant material are described herein. The active agents used to control these pathogens are tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives, analogues or modifications thereof.
    Type: Application
    Filed: August 22, 2013
    Publication date: January 29, 2015
    Inventors: Marina Rautenbach, Abré De Beer, Anscha Mari Troskie, Johan Arnold Vosloo
  • Publication number: 20150024996
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Application
    Filed: March 27, 2014
    Publication date: January 22, 2015
    Applicant: IMPRIMIS PHARMACEUTICALS, INC.
    Inventors: Jeffrey T. LIEGNER, John Scott Karolchyk, Bernard Covalesky, Richard Dilzer, Kallan Peters
  • Publication number: 20150025511
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Application
    Filed: August 15, 2014
    Publication date: January 22, 2015
    Applicant: IMPRIMIS PHARMACEUTICALS, INC.
    Inventors: William F. WILEY, Richard Dilzer
  • Patent number: 8937040
    Abstract: Provided herein is an antibacterial compound of the following formula: or a pharmaceutically acceptable salt thereof. The antibacterial compound has antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provided are antibacterial pharmaceutical compositions containing the antibacterial compound, as well as methods for preparing the antibacterial compound.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 20, 2015
    Assignee: BioSource Pharm, Inc.
    Inventor: Richard A. Leese
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Patent number: 8933017
    Abstract: A method for treatment of infection with Listeria spp., Plasmodium spp., or Shigella spp. includes administering a peptide or a pharmaceutically acceptable salt of the peptide to an individual in need of treatment for the infection.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: January 13, 2015
    Assignee: Karlsruher Institut fur Technologie
    Inventors: Christian Jung, Véronique Orian-Rousseau, Alexandra Matzke, Helmut Ponta
  • Publication number: 20150011465
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.
    Type: Application
    Filed: September 9, 2014
    Publication date: January 8, 2015
    Inventors: Kent Kirshenbaum, Sung Bin Shin
  • Patent number: 8921309
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 30, 2014
    Assignee: Uniquest Pty Limited
    Inventors: Rustum S. Boyce, Joseph Cherian, Cleofe Calanasan, Muhammad Sofian Asi Sihombing
  • Publication number: 20140371135
    Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
    Type: Application
    Filed: September 2, 2014
    Publication date: December 18, 2014
    Applicant: Cubist Pharmaceuticals, Inc.
    Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
  • Publication number: 20140356457
    Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test com
    Type: Application
    Filed: April 7, 2014
    Publication date: December 4, 2014
    Applicant: UNIVERSITY OF GENEVA
    Inventors: Karl-Heinz KRAUSE, Botond BANFI
  • Patent number: 8889826
    Abstract: Disclosed herein are novel peptides and protected peptides. These compounds can be derived from naturally occurring peptides, such as those selected from colistin, circulin A, polymyxin A, polymyxin B, polymyxin D, octapeptin B, octapeptin C, and [Ile7]polymyxin B1. Also disclosed are pharmaceutical compositions containing the new peptides, as well as methods for preparing the novel peptides and protected peptides.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: November 18, 2014
    Assignee: BioSource Pharm, Inc.
    Inventors: Richard A. Leese, Noreen Francis, William V. Curran, Donald B. Borders, Howard Jarolmen
  • Publication number: 20140328896
    Abstract: Provided are methods and compositions for enhancing the gastrointestinal health of an animal in need thereof by administering a gastrointestinal health maintaining or improving amount of a composition comprising an effective amount of lactic acid. The administered composition may also comprise one or more prebiotic, probiotic, symbiotic, anti bacterial, or anti-diarrhea agents.
    Type: Application
    Filed: December 29, 2011
    Publication date: November 6, 2014
    Applicant: HILL'S PET NUTRITION, INC.
    Inventors: Dennis Jewll, Luis J. Montelongo, Sarah Martinez, Lynda Melendez
  • Patent number: 8877738
    Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: November 4, 2014
    Assignee: Spiderbiotech S.r.L.
    Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Publication number: 20140315790
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
    Type: Application
    Filed: April 17, 2013
    Publication date: October 23, 2014
    Inventors: Simon Bushell, Matthew J, LaMarche, Michael A. Patane, Lewis Whitehead
  • Publication number: 20140308347
    Abstract: The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed.
    Type: Application
    Filed: November 13, 2012
    Publication date: October 16, 2014
    Applicant: JAWAHARLAL NEHRU CENTRE FOR ADVANCED
    Inventors: Jayanta Haldar, Yarlagadda Venkateswarlu, Padma Akkapeddi
  • Publication number: 20140303071
    Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventor: Deborah O'NEIL
  • Publication number: 20140296133
    Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.
    Type: Application
    Filed: October 11, 2012
    Publication date: October 2, 2014
    Applicant: Council of Scientific & Industrial Research
    Inventors: Dumbala Srinivasa Reddy, Seetharam Singh Balamkundu, Remya Ramesh
  • Publication number: 20140296134
    Abstract: Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample.
    Type: Application
    Filed: November 8, 2012
    Publication date: October 2, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Tor Savidge, Sara Dann
  • Publication number: 20140294925
    Abstract: Provided herein are methods of treating a superbug infection in a subject that include administering to the subject a therapeutically effective dose of ramoplanin in combination with a therapeutically effective dose of one or more rhamnolipids, thereby treating the superbug infection. The superbug may be vancomycin-resistant Enterococcus, Clostridium difficile, or multidrug-resistant Clostridium difficile. The one or more rhamnolipids may include monorhamnolipid Rha-C10-C10, dirhamnolipid Rha-Rha-C10-C10, or monorhamnolipid Rha-C10-C10 and dirhamnolipid Rha-Rha-C10-C10. Also disclosed are pharmaceutical compositions that include ramoplanin, one or more rhamnolipids, and a pharmaceutically acceptable carrier, as well as formulations for preventing superbug infection.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 2, 2014
    Applicant: AGAE Technologies LLC
    Inventor: Xihou Yin
  • Patent number: 8846610
    Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: September 30, 2014
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Dennis Keith, Jan-Ji Lai, Chandrika Govardhan, Nazer Khalaf